Saturday 17 October 2026
Export TCRT’s income statement to Excel — free account
Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
2.63
0.45
+20.64%
Follow TCRT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(145.61%) | (198.10%) | (350.30%) | (185.95%) | |
Piotroski F-Score |
— | 3 | — | — | |
| (110.64%) | (145.99%) | (205.30%) | (128.30%) | ||
ROIC |
(294.22%) | (343.83%) | (277.37%) | (480.35%) | |
Return on Tangible Assets |
(216.23%) | (329.86%) | (899.12%) | 3,233.87% | |
Average Days of Receivables |
— | 78.21 | — | — | |
Free Cash Flow per Share |
(0.75) | (0.75) | (1.61) | (1.12) | |
Free Cash Flow |
(1.64) | (1.46) | (3.13) | (2.73) | |
Capital Expenditures |
1.27 | 1.41 | — | — | |
| Other line items | |||||
Cash ROIC |
(34.53%) | (41.35%) | (190.50%) | (351.42%) | |
Accounts Receivable Turnover |
— | 4.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 9,735.71% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 20,478.57% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 2,957.14% | 0.00% | 0.00% | |
Operating CF/Net income |
0.72 | 0.69 | 0.76 | 0.68 | |
Depreciation/Fixed assets |
0.00 | 0.08 | 0.17 | 0.31 | |
Capex/Depreciation |
0.00 | 200.86 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (1.47) | (1.61) | (1.12) | |
Capex per Share |
0.58 | 0.72 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (100.43) | — | — |
Columns are period end dates